FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4226289380> ?p ?o ?g. }

• W4226289380 endingPage "71" @default.
• W4226289380 startingPage "62" @default.
• W4226289380 abstract "In Poland, treatment with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors has become available free of charge in a therapeutic program. Assessed herein, is the efficacy and safety of alirocumab and evolocumab in patients with heterozygous familial hypercholesterolemia (FH).Data of 55 adult FH patients who participated in the program were analyzed upon meeting the criteria established by the Ministry of Health (low density lipoprotein cholesterol [LDL-C] above 160 mg/dL on max. tolerated statin dose and ezetimib). The efficacy of PCSK9 inhibitors in reducing LDL-C with drug administration every 2 weeks was assessed after 3 months and 1 year of therapy. A safety profile evaluation was performed at each visit. 48 patients completed the 3-month and 21 for the 1-year observation periods (34 patients treated with alirokumab and 14 with evolocumab).The mean concentration of direct-measured LDL-C decreased from the initial level of 215.1 ± 74.5 mg/dL to 75.3 ± 64.1 mg/dL, i.e., by 65 ± 14% following 3 months of treatment. This effect was stable in 1-year observation (77.7 ± 72.8 mg/dL). Adverse effects were flu-like symptoms (13.0%), injection site reactions (11.1%), fatigue (5.6%) and musculoskeletal symptoms (5.6%). Seven patients failed to complete the 3-month treatment period due to side effects or non-compliance, and 1 patient failed to complete the 1-year treatment due to myalgia.This study confirmed high effectiveness of PCSK9 inhibitors in reducing LDL-C levels in patients with FH. Due to restrictive inclusion criteria with LDL-C threshold level > 160 mg/dL (> 4.1 mmol/L) required for participation in the therapeutic program, a relatively small number of FH patients were eligible for treatment." @default.
• W4226289380 created "2022-05-05" @default.
• W4226289380 creator A5011398439 @default.
• W4226289380 creator A5014415262 @default.
• W4226289380 creator A5016232008 @default.
• W4226289380 creator A5029856826 @default.
• W4226289380 creator A5033424309 @default.
• W4226289380 creator A5037107615 @default.
• W4226289380 creator A5041703351 @default.
• W4226289380 creator A5045030856 @default.
• W4226289380 creator A5054072132 @default.
• W4226289380 creator A5054475556 @default.
• W4226289380 creator A5062386370 @default.
• W4226289380 creator A5071808522 @default.
• W4226289380 creator A5071910957 @default.
• W4226289380 creator A5072797499 @default.
• W4226289380 creator A5075732859 @default.
• W4226289380 creator A5082600585 @default.
• W4226289380 creator A5083742178 @default.
• W4226289380 creator A5084148001 @default.
• W4226289380 date "2022-02-23" @default.
• W4226289380 modified "2023-10-18" @default.
• W4226289380 title "Effectiveness and safety of PCSK9 inhibitor therapy in patients with familial hypercholesterolemia within a therapeutic program in Poland: Preliminary multicenter data" @default.
• W4226289380 cites W1898803325 @default.
• W4226289380 cites W1962272706 @default.
• W4226289380 cites W2001328643 @default.
• W4226289380 cites W2104299102 @default.
• W4226289380 cites W2165624352 @default.
• W4226289380 cites W2408718933 @default.
• W4226289380 cites W2418398900 @default.
• W4226289380 cites W2519905430 @default.
• W4226289380 cites W2594072057 @default.
• W4226289380 cites W2596179513 @default.
• W4226289380 cites W2757199879 @default.
• W4226289380 cites W2762069281 @default.
• W4226289380 cites W2766232664 @default.
• W4226289380 cites W2768968665 @default.
• W4226289380 cites W2774009850 @default.
• W4226289380 cites W2787114034 @default.
• W4226289380 cites W2806550872 @default.
• W4226289380 cites W2899997727 @default.
• W4226289380 cites W2944503309 @default.
• W4226289380 cites W2953804067 @default.
• W4226289380 cites W2989910051 @default.
• W4226289380 cites W3004830249 @default.
• W4226289380 cites W3024375461 @default.
• W4226289380 cites W3028800184 @default.
• W4226289380 cites W3183857127 @default.
• W4226289380 doi "https://doi.org/10.5603/cj.a2022.0003" @default.
• W4226289380 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35146730" @default.
• W4226289380 hasPublicationYear "2022" @default.
• W4226289380 type Work @default.
• W4226289380 citedByCount "0" @default.
• W4226289380 crossrefType "journal-article" @default.
• W4226289380 hasAuthorship W4226289380A5011398439 @default.
• W4226289380 hasAuthorship W4226289380A5014415262 @default.
• W4226289380 hasAuthorship W4226289380A5016232008 @default.
• W4226289380 hasAuthorship W4226289380A5029856826 @default.
• W4226289380 hasAuthorship W4226289380A5033424309 @default.
• W4226289380 hasAuthorship W4226289380A5037107615 @default.
• W4226289380 hasAuthorship W4226289380A5041703351 @default.
• W4226289380 hasAuthorship W4226289380A5045030856 @default.
• W4226289380 hasAuthorship W4226289380A5054072132 @default.
• W4226289380 hasAuthorship W4226289380A5054475556 @default.
• W4226289380 hasAuthorship W4226289380A5062386370 @default.
• W4226289380 hasAuthorship W4226289380A5071808522 @default.
• W4226289380 hasAuthorship W4226289380A5071910957 @default.
• W4226289380 hasAuthorship W4226289380A5072797499 @default.
• W4226289380 hasAuthorship W4226289380A5075732859 @default.
• W4226289380 hasAuthorship W4226289380A5082600585 @default.
• W4226289380 hasAuthorship W4226289380A5083742178 @default.
• W4226289380 hasAuthorship W4226289380A5084148001 @default.
• W4226289380 hasBestOaLocation W42262893801 @default.
• W4226289380 hasConcept C126322002 @default.
• W4226289380 hasConcept C197934379 @default.
• W4226289380 hasConcept C2776839432 @default.
• W4226289380 hasConcept C2778114629 @default.
• W4226289380 hasConcept C2778163477 @default.
• W4226289380 hasConcept C2778616394 @default.
• W4226289380 hasConcept C2779120738 @default.
• W4226289380 hasConcept C2780072125 @default.
• W4226289380 hasConcept C2780745583 @default.
• W4226289380 hasConcept C2780902209 @default.
• W4226289380 hasConcept C2780948078 @default.
• W4226289380 hasConcept C43554185 @default.
• W4226289380 hasConcept C71924100 @default.
• W4226289380 hasConcept C90924648 @default.
• W4226289380 hasConceptScore W4226289380C126322002 @default.
• W4226289380 hasConceptScore W4226289380C197934379 @default.
• W4226289380 hasConceptScore W4226289380C2776839432 @default.
• W4226289380 hasConceptScore W4226289380C2778114629 @default.
• W4226289380 hasConceptScore W4226289380C2778163477 @default.
• W4226289380 hasConceptScore W4226289380C2778616394 @default.
• W4226289380 hasConceptScore W4226289380C2779120738 @default.
• W4226289380 hasConceptScore W4226289380C2780072125 @default.
• W4226289380 hasConceptScore W4226289380C2780745583 @default.
• W4226289380 hasConceptScore W4226289380C2780902209 @default.
• W4226289380 hasConceptScore W4226289380C2780948078 @default.

• next